Skip to main content

Lidocaine 5% Transdermal Patch Shortage

Last Updated: May 7, 2024
Status: Current

Products Affected - Description
    • Lidoderm transdermal patch, Endo Pharmaceuticals, 5%, 30 count, NDC 63481-0687-06 - discontinued
    • Lidocaine transdermal patch, Par Pharmaceuticals, 5%, 30 count, NDC 00603-1880-16
    • Lidocaine transdermal patch, Teva, 5%, 30 count, NDC 00591-3525-30
Reason for the Shortage
    • Amneal has lidocaine 5% transdermal patches available.
    • Endo discontinued Lidoderm patches in January 2023.
    • Mylan has lidocaine 5% transdermal patches available.
    • Par did not provide a reason for the shortage.
    • Teva did not provide a reason for the shortage.
    • Yaral Pharma has lidocaine 5% transdermal patches available.
Available Products
    • Lidocaine transdermal patch, Amneal, 5%, 30 count, NDC 65162-0791-08
    • Lidocaine transdermal patch, Mylan (Viatris), 5%, 30 count, NDC 00378-9055-93
    • Lidocaine transdermal patch, Yaral Pharma, 5%, 30 count, NDC 82347-0505-05

Estimated Resupply Dates

    • Par has lidocaine 5% transdermal patches in 30 count boxes in limited supply.
    • Teva has lidocaine 5% transdermal patches in 30 count boxes on back order and the company estimates a release date in early-June 2024.

Updated

Updated May 7, 2024 by Leslie Jensen, PharmD, Drug Information Specialist. Created November 9, 2022 by Leslie Jensen, PharmD, Drug Information Specialist. © 2024, Drug Information Service, University of Utah, Salt Lake City, UT.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer